Patents by Inventor Brittan L. Pasloske
Brittan L. Pasloske has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140099715Abstract: The present invention provides improved methods of attenuating gene expression through the phenomenon of RNA interference. The invention provides methods of synthesis of double stranded RNAs (dsRNAs) of increased potency for use as small interfering RNA (siRNA). Surprisingly and unexpectedly, siRNAs made by the methods of the invention are significantly more potent than previously available siRNAs.Type: ApplicationFiled: August 21, 2013Publication date: April 10, 2014Applicant: Applied Biosystems, LLCInventors: David Brown, Lance P. Ford, Vince Pallotta, Brittan L. Pasloske, Richard A. Jarvis
-
Patent number: 8524680Abstract: The present invention provides improved methods of attenuating gene expression through the phenomenon of RNA interference. The invention provides methods of synthesis of double stranded RNAs (dsRNAs) of increased potency for use as small interfering RNA (siRNA). Surprisingly and unexpectedly, siRNAs made by the methods of the invention are significantly more potent than previously available siRNAs.Type: GrantFiled: August 31, 2009Date of Patent: September 3, 2013Assignee: Applied Biosystems, LLCInventors: David Brown, Lance P. Ford, Richard A. Jarvis, Vince Pallotta, Brittan L. Pasloske
-
Publication number: 20130143275Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.Type: ApplicationFiled: September 14, 2012Publication date: June 6, 2013Applicant: Applied Biosystems, LLCInventors: Brittan L. PASLOSKE, Quoc Hoang
-
Patent number: 8426126Abstract: The invention relates to methods of separating polynucleotides, such as DNA, RNA and PNA, from solutions containing polynucleotides by reversibly binding the polynucleotides to a solid surface, such as a magnetic microparticle.Type: GrantFiled: September 30, 2004Date of Patent: April 23, 2013Assignee: Applied Biosystems, LLCInventors: Gary J. Latham, Xingwang Fang, Richard C. Conrad, Jon A. Kemppainen, Robert A. Setterquist, Brittan L. Pasloske
-
Publication number: 20120322112Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.Type: ApplicationFiled: May 3, 2012Publication date: December 20, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brittan L. Pasloske, Quoc Hoang
-
Publication number: 20120183962Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.Type: ApplicationFiled: January 17, 2012Publication date: July 19, 2012Applicant: APPLIED BIOSYSTEMS, LLCInventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
-
Publication number: 20120065105Abstract: Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified.Type: ApplicationFiled: July 26, 2011Publication date: March 15, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: R. Scott Kuersten, Brittan L. Pasloske
-
Patent number: 8114594Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.Type: GrantFiled: June 23, 2009Date of Patent: February 14, 2012Assignee: Applied Biosysyems, LLCInventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
-
Publication number: 20110257375Abstract: Described herein is the use of antibody-based delivery agents to target and deliver nucleic acid agents into specific cell types. Herein, we describe methods used that improve the ability of conjugates that load over 3 siRNA per conjugate and target siRNA to cells expressing the appropriate cell surface antigens. We also contemplate the use of antibody, targeting peptides, small molecules, aptamers and all other factors known in the art that can specifically target tissues. In each case, these targeting moieties can be conjugated using chemical crosslinking agents to carriers enabling directed delivery of nucleic acids.Type: ApplicationFiled: February 11, 2009Publication date: October 20, 2011Inventors: Lance P. Ford, Joe Krebs, Brittan L. Pasloske
-
Patent number: 8008010Abstract: Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified.Type: GrantFiled: June 27, 2008Date of Patent: August 30, 2011Assignee: Applied Biosystems, LLCInventors: R. Scott Kuersten, Brittan L. Pasloske
-
Publication number: 20100184039Abstract: The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi.Type: ApplicationFiled: September 28, 2009Publication date: July 22, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Lance P. Ford, Mike Byrom, Brittan L. Pasloske
-
Publication number: 20100167287Abstract: The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.Type: ApplicationFiled: June 23, 2009Publication date: July 1, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brittan L. Pasloske, Xingwang Fang, Quoc Hoang
-
Publication number: 20090286304Abstract: The present invention concerns a compositions and method for isolating a nucleic acid from a cell-containing sample. There is disclosed a method comprising obtaining at least one cell-containing sample, which comprises a cell containing nucleic acid, obtaining at least one catabolic enzyme, obtaining at least one nuclease inhibitor, preparing an admixture of the sample, the catabolic enzyme, and the nuclease inhibitor, maintaining the admixture under conditions where the catabolic enzyme is active, and agitating the admixture, where the sample is digested to produce a nucleic acid-containing lysate of the sample.Type: ApplicationFiled: May 11, 2009Publication date: November 19, 2009Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Gary Latham, Brittan L. Pasloske, Heidi Peltier
-
Patent number: 7445901Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. A preferred embodiment comprises at least two nuclease inhibitors, and is referred to as a nuclease inhibitor cocktail. In some specific embodiments, the invention concerns methods of performing in vitro translation comprising obtaining a first nuclease inhibitor, which inhibitor is further defined as an anti-nuclease antibody, and placing the anti-nuclease antibody in an in vitro translation reaction. In many cases, the in vitro translation reaction comprises at least one nuclease, which may be a ribonuclease, a deoxyribonuclease, or a nonspecific nuclease.Type: GrantFiled: December 6, 2006Date of Patent: November 4, 2008Assignee: Applera CorporationInventors: W. Antoni Kudlicki, Matthew M. Winkler, Brittan L. Pasloske
-
Patent number: 7264932Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by using nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors.Type: GrantFiled: February 25, 2004Date of Patent: September 4, 2007Assignee: Applera CorporationInventors: Gary J. Latham, Matthew M. Winkler, Brittan L. Pasloske, W. Antoni Kudlicki
-
Patent number: 7163793Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases. A preferred embodiment comprises at least two nuclease inhibitors, and is referred to as a nuclease inhibitor cocktail. In some specific embodiments, the invention concerns methods of performing in vitro translation comprising obtaining a first nuclease inhibitor, which inhibitor is further defined as an anti-nuclease antibody, and placing the anti-nuclease antibody in an in vitro translation reaction. In many cases, the in vitro translation reaction comprises at least one nuclease, which may be a ribonuclease, a deoxyribonuclease, or a nonspecific nuclease.Type: GrantFiled: September 30, 2003Date of Patent: January 16, 2007Assignee: Ambion, Inc.Inventors: W. Antoni Kudlicki, Matthew M. Winkler, Brittan L. Pasloske
-
Patent number: 7033749Abstract: The present invention relates to nuclease resistant nucleic acids in general and ribonuclease resistant RNAs in particular. Methods of making and using such nucleic acids are disclosed.Type: GrantFiled: April 10, 2002Date of Patent: April 25, 2006Assignees: Ambion, Inc., Cenetron Diagnostics LLCInventors: Brittan L. Pasloske, Dwight B. DuBois, David M. Brown, Matthew M. Winkler
-
Publication number: 20040248094Abstract: The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi.Type: ApplicationFiled: June 12, 2002Publication date: December 9, 2004Inventors: Lance P. Ford, Mike Byrom, Brittan L. Pasloske
-
Patent number: 6825340Abstract: The present invention is a general method for inactivating or inhibiting ribonucleases. Ribonucleases are treated with a reducing agent and heat. RNA samples contaminated with ribonuclease may be treated with this method to protect them from degradation. The RNA may then be used directly in a variety of enzymatic reactions and molecular biology techniques. This method may also be applied to a variety of molecular biology reagents which may be contaminated with ribonuclease to protect an RNA from being degraded when incubated with the reagent.Type: GrantFiled: March 23, 2001Date of Patent: November 30, 2004Assignee: Ambion, Inc.Inventors: Brittan L. Pasloske, William Wu
-
Patent number: 6777210Abstract: The present invention is a general method for irreversibly inactivating ribonucleases. Ribonucleases are completely inactivated by treating them with a reducing agent and heat. RNA samples contaminated with ribonuclease may be treated with this method to protect them from degradation. The RNA may then be used directly in a variety of enzymatic reactions and molecular biology techniques. This method may also be applied to a variety of molecular biology reagents which may be contaminated with ribonuclease to protect an RNA from being degraded when incubated with the reagent.Type: GrantFiled: September 24, 1998Date of Patent: August 17, 2004Assignee: Ambion, Inc.Inventors: Brittan L. Pasloske, William Wu